19th December 2017 - 08:00 PST; 11:00 EST; 16:00 GMT; 17:00 CET
The promising early clinical data from gene therapies for rare diseases has seen a resurgence in investment and optimism in the field. This webinar provides an opportunity to hear from three leading experts at the forefront of developing these potentially curative therapies:
- Dr Sven Kili, VP and Head of Cell & Gene Therapy Development, GSK, UK
- Mr Geoff MacKay, CEO, AVROBIO, USA
- Dr Sue Washer, CEO, AGTC, USA
They'll share their insights and experiences in navigating the commercialization path, including:
- What factors are unique to rare disease that need to be considered in terms of demonstrating clinical efficacy and selecting clinical endpoints?
- The different types of accelerated approval tracks available for rare and ultra rare diseases and what do you need to demonstrate in order to gain approval?
- Reimbursement price points and how rare disease companies can establish a viable business strategy to support different payment models?
- How feasible is it to drive down manufacturing costs at small scale for niche patient therapies?
By registering to view this Webinar you are also signing up as a member of Cell & Gene Therapy Insights and agree to be contacted by Phacilitate. We will email you a username and password so you can read all our open access content.
Dr Sven Kili
VP and Head of Cell and Gene Therapy Development, GSK, UK Dr Sven Kili is the VP and Development Head for the Gene Therapy division of GSK where he leads the teams developing ex-vivo Gene Therapies for a variety of genetic disorders. They are currently developing solutions for a number of diseases including ADA-SCID; WAS; Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia. Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development and medical affairs activities culminating in the granting of the first combined ATMP approval in the EU for MACI®. His team also prepared and submitted regulatory filings for Australia and the US, including health technology assessments. Before joining Genzyme, Sven worked for Geistlich Pharma where, in addition to leading the cell therapy medical activities, he oversaw all UK regulatory functions and was the QPPV for the EU. Sven trained as an Orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practise has developed expertise Cell and Gene Therapy in clinical development, regulatory compliance, value creation, risk management and product safety, product launches and post-marketing activities. He sits on the board of a Swedish Stem Cell company and still maintains his clinical skills in the UK NHS and serves as an ATLS Instructor in his spare time.
Mr Geoff MacKay
CEO, AVROBIO, USA
Geoff is an experienced CEO with proven success leading innovative businesses. While CEO of Organogenesis Inc., the company treated 1 million patients with living cell therapies, received the first FDA CBER allogeneic cell-therapy approval and achieved an unparalleled position within regenerative medicine. Geoff was founding CEO of eGenesis, applying CRISPR Cas-9 gene editing to xenotransplantation. Geoff spent 11 years at Novartis in senior leadership positions within the Global Transplantation & Immunology franchise. Past activities include Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, and Advisory Council to the Health Policy Commission for Massachusetts. Through his public and private enterprise work, Geoff is dedicated to applying innovation to reshape and improve the quality of healthcare.
Ms Sue Washer
President and CEO, AGTC, USA
An experienced entrepreneur with a strong scientific and operational background, Sue brings a decade of experience in pharmaceutical management and research with Abbott Labs and Eli Lilly & Company and more than 16 years of senior management experience with entrepreneurial firms in Florida including three start-ups. At AGTC, Sue has successfully secured investments of more than $91 million from nationally recognized venture capitalists and granting agencies; negotiated and closed on a major collaboration with a top five Biotech company; lead the company to complete critical milestones; and recruited an experienced management team. Her experience as a group leader with Abbott’s Diagnostic Division helped hone her skills in bringing new products and technologies from the lab bench into the market place. Sue is the chair of Southeast BIO, is a member of the Executive Committee of BioFlorida and sits on the board of the Florida High Tech Corridor Council. She has a degree in biochemistry from Michigan State University and an MBA from the University of Florida where she was one of the first graduates from the Warrington College of Business Entrepreneurship program.